Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 23 h ago

Yarrow Bioscience, Inc.: ADAR1 Capital Management, LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 17 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

ADAR1 Capital Management, LLC amended its Schedule 13G filing for Yarrow Bioscience, Inc., according to SEC accession 0001104659-26-128736. The amendment updates the investment firm's reported beneficial ownership position in the biotech company, though the filing notice did not disclose specific share counts or percentage stakes. Schedule 13G amendments are typically filed when a passive investor's ownership crosses the 5% threshold or when previously reported figures change materially. The filing signals continued institutional interest in Yarrow Bioscience and gives investors a refreshed view of ADAR1's position. Market participants will watch for the full filing details to gauge the size and direction of the stake change.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Yarrow Bioscience, Inc., ADAR1 Capital Management, LLC